The role of PDGFRA as a therapeutic target in young colorectal cancer patients.

Tae Won KimHye Kyung HongChung LeeSunmin KimWoo Yong LeeSeong Hyeon YunHee Cheol KimJung Wook HuhYoon Ah ParkJe-Gun JoungWoong-Yang ParkYong Beom Cho

Published in: Journal of translational medicine (2021)

Our study suggests that CRC in young patients is associated with CMS4 and PDGFRA. In addition, PDGFRA may serve potential of novel therapeutic strategies and represent a predictive biomarker of response to regorafenib for young CRC patients.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
middle aged
patient reported outcomes